Sage Therapeutics Inc. (Nasdaq: SAGE) reported positive results from a Phase 2 double-blind, placebo-controlled clinical trial of SAGE-217 to treat moderate to severe major depressive disorder. Shares of the biopharmaceutical leaped $64.37 to close at $156.27.